|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
ocn841232986 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130430s2013 nyu ob 001 0 eng d |
| 010 |
|
|
|z 2012952790
|
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d E7B
|d YDXCP
|d UKMGB
|d OCLCF
|d OCLCQ
|d EBLCP
|d NKT
|d AZK
|d DEBSZ
|d AGLDB
|d ICA
|d MOR
|d PIFPO
|d MERUC
|d OCLCQ
|d ZCU
|d U3W
|d D6H
|d STF
|d WRM
|d VTS
|d COCUF
|d NRAMU
|d ICG
|d AU@
|d OCLCQ
|d DKC
|d OCLCQ
|d M8D
|d OCLCQ
|d AJS
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCL
|
| 016 |
7 |
|
|a 016317224
|2 Uk
|
| 019 |
|
|
|a 923665593
|a 961655037
|a 962649338
|a 988437273
|a 991996760
|a 1037910501
|a 1038577728
|a 1045481197
|a 1059018498
|a 1097130106
|
| 020 |
|
|
|a 9781624174087
|q (electronic bk.)
|
| 020 |
|
|
|a 1624174086
|q (electronic bk.)
|
| 020 |
|
|
|z 162417406X
|
| 020 |
|
|
|z 9781624174063
|
| 035 |
|
|
|a (OCoLC)841232986
|z (OCoLC)923665593
|z (OCoLC)961655037
|z (OCoLC)962649338
|z (OCoLC)988437273
|z (OCoLC)991996760
|z (OCoLC)1037910501
|z (OCoLC)1038577728
|z (OCoLC)1045481197
|z (OCoLC)1059018498
|z (OCoLC)1097130106
|
| 050 |
|
4 |
|a RC662.4
|b .I57 2013eb
|
| 072 |
|
7 |
|a HEA
|x 039050
|2 bisacsh
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Insulin Resistance :
|b New Developments /
|c John Freeman and Scott Newman, editors.
|
| 260 |
|
|
|a New York :
|b Nova Science,
|c ©2013.
|
| 300 |
|
|
|a 1 online resource (ix, 113 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Endocrinology research and clinical developments
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a INSULIN RESISTANCE ; INSULIN RESISTANCE ; CONTENTS ; PREFACE ; PATHOPHYSIOLOGICAL BASISFOR ANTIOXIDANT THERAPY OF INSULIN RESISTANCE ; ABSTRACT ; INTRODUCTION ; PATHOPHYSIOLOGY OF INSULIN RESISTANCE ; Insulin-Resistance: Mechanisms of Disease ; Glucose Toxicity in IR; IR and Oxidative Stress Cross-Talking ; Polyol Pathway; Glucosamine Pathway; Kinase C Protein Activation ; TNF-alpha Activate JNK ; Advanced Glycation End Products and Oxidative Stress (AGEs) ; ANTIOXIDANT THERAPY IN INSULIN-RESISTANCE ; Resveratrol ; Antioxidant Effect of Resveratrol in Hepatoprotection.
|
| 505 |
8 |
|
|a Antioxidant Effect of Resveratrol in Pancreatic Protection Anti-Obesity Effects ; Anti-Diabetic Effects ; Antioxidant Vitamins ; Flavonoids ; Other Antioxidants ; CONCLUSION AND PERSPECTIVES ; REFERENCES ; NEW INSIGHT INTO THE REGULATION OF INSULIN RESISTANCE ; ABSTRACT ; 1. INTRODUCTION ; 2. THE EFFECT OF ENDOCRINE HORMONES ON INSULIN RESISTANCE ; 2.1. Galanin and Insulin Resistance ; 2.2. Ghrelin and Insulin Resistance ; 2. 3. Leptin and Insulin Resistance ; 2.4. Adiponectin and Insulin Resistance ; 2.5. RBP4 and Insulin Resistance.
|
| 505 |
8 |
|
|a 3. THE ROLE OF THE AUTONOMIC NERVOUS SYSTEM IN REGULATING INSULIN RESISTANCE 4. THE GASTROINTESTINAL TRACT MICROBIOTA IN THE DEVELOPMENT OF INSULIN RESISTANCE ; 5. PPARS AND INSULIN RESISTANCE ; 6. VITAMIN D DEFICIENCY IN THE DEVELOPMENT OF INSULIN RESISTANCE ; 7. CURRENT GUIDELINES ON RISK FACTORS FOR INSULIN RESISTANCE, DIRECT AND INDIRECT INSULIN RESISTANCE ASSESSMENT METHODS ; 7.1. CRP; 7.2. Hyperinsulinemic Euglycemic Glucose Clamp ; 7.3. Oral Glucose Tolerance Test; 7. 4. HOMA- Insulin Resistance (IR) ; 8. THE NEW INSIGHT INTO PRIMARY PREVENTION AND THERAPY OF INSULIN RESISTANCE.
|
| 505 |
8 |
|
|a 8.1. SGLT2 8.2. MicroRNAs ; CONCLUSION ; REFERENCES ; INSULIN RESISTANCE AFTER SEVERE BURN INJURY ; ABSTRACT ; ABBREVIATIONS ; INTRODUCTION ; MATERIALS AND METHODS ; RESULTS ; Blood Glucose Levels before and after EIC ; PET Study of Glucose Uptake, Oxygen Extraction Fraction and Blood Flow in Hind Limb Skeletal Muscle ; Changes in Endogenous Glucose Production After EIC ; DISCUSSION ; ACKNOWLEDGMENTS ; REFERENCES ; LIPOPROTEIN LIPASE AND INSULIN RESISTANCE ; ABSTRACT ; INTRODUCTION ; BACKGROUND OF LIPOPROTEIN LIPASE (LPL) ; RELATIONSHIP BETWEEN LPL AND LIPID METABOLISM AND ATHEROSCLEROSIS.
|
| 505 |
8 |
|
|a EFFECT OF LPL ACTIVATOR NO-1886 ON LPL, LIPID METABOLISM AND ATHEROSCLEROSIS EFFECT OF LPL ACTIVATOR NO-1886 ON FATTY LIVER ; RELATIONSHIP BETWEEN LPL AND OBESITY AND INSULIN RESISTANCE ; REFERENCES ; INDEX.
|
| 650 |
|
0 |
|a Insulin resistance.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Diabetes.
|2 bisacsh
|
| 650 |
|
7 |
|a Insulin resistance
|2 fast
|
| 700 |
1 |
|
|a Freeman, John.
|
| 700 |
1 |
|
|a Newman, Scott.
|
| 758 |
|
|
|i has work:
|a Insulin resistance (Text)
|1 https://id.oclc.org/worldcat/entity/E39PD3mhMBPJmWkYtpFjCBqrtq
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Insulin resistance.
|d [S.l.] : Nova Science, 2013
|z 162417406X
|w (OCoLC)818735141
|
| 830 |
|
0 |
|a Endocrinology research and clinical developments.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=3021284
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|